These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1813 related items for PubMed ID: 15760966

  • 1. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grøndahl ML, Westergaard L, Andersen CY.
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [Abstract] [Full Text] [Related]

  • 2. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
    Humaidan P, Ejdrup Bredkjaer H, Westergaard LG, Yding Andersen C.
    Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959
    [Abstract] [Full Text] [Related]

  • 3. Hormonal characteristics of follicular fluid from women receiving either GnRH agonist or hCG for ovulation induction.
    Andersen CY, Humaidan P, Ejdrup HB, Bungum L, Grøndahl ML, Westergaard LG.
    Hum Reprod; 2006 Aug; 21(8):2126-30. PubMed ID: 16682403
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study.
    Pirard C, Donnez J, Loumaye E.
    Hum Reprod; 2006 Jul; 21(7):1894-900. PubMed ID: 16556673
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
    Cavagna M, Maldonado LG, de Souza Bonetti TC, de Almeida Ferreira Braga DP, Iaconelli A, Borges E.
    Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Fatemi HM, Polyzos NP, van Vaerenbergh I, Bourgain C, Blockeel C, Alsbjerg B, Papanikolaou EG, Humaidan P.
    Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes.
    Papanikolaou EG, Bourgain C, Kolibianakis E, Tournaye H, Devroey P.
    Hum Reprod; 2005 Jun; 20(6):1541-7. PubMed ID: 15705618
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, Bustion S, Loumaye E, Fauser BC.
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. GnRH antagonists in ovarian stimulation for IVF.
    Tarlatzis BC, Fauser BC, Kolibianakis EM, Diedrich K, Rombauts L, Devroey P.
    Hum Reprod Update; 2006 Sep; 12(4):333-40. PubMed ID: 16567347
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM, Bates GW, Robinson RD, Arthur NJ, Martin JE, Neal GS.
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [Abstract] [Full Text] [Related]

  • 20. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle.
    Kahraman K, Berker B, Atabekoglu CS, Sonmezer M, Cetinkaya E, Aytac R, Satiroglu H.
    Fertil Steril; 2009 Jun; 91(6):2437-44. PubMed ID: 18555238
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 91.